Managed Healthcare Executive April 30, 2024
MHE Staff

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium talks about the disappointment surrounding the uptake of Humira biosimilars.

Lockhart spoke about biosimilars at...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Related Articles:
Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA’s 2024 Update
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
AZ plots $1.5B antibody-drug conjugate plant in Asia
STAT+: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality
Pharma Pulse 5/20/24: The Future of RBQM Adoption, AI Innovating Pregnancy Care and Cancer Screening & more

Share This Article